Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Common Equity (2017 - 2025)

Historic Common Equity for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to $50.9 million.

  • Vistagen Therapeutics' Common Equity fell 3723.03% to $50.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $50.9 million, marking a year-over-year decrease of 3723.03%. This contributed to the annual value of $70.4 million for FY2025, which is 3840.89% down from last year.
  • Vistagen Therapeutics' Common Equity amounted to $50.9 million in Q4 2025, which was down 3723.03% from $66.3 million recorded in Q3 2025.
  • Vistagen Therapeutics' 5-year Common Equity high stood at $123.3 million for Q4 2023, and its period low was $6.8 million during Q2 2023.
  • In the last 5 years, Vistagen Therapeutics' Common Equity had a median value of $68.4 million in 2025 and averaged $65.7 million.
  • In the last 5 years, Vistagen Therapeutics' Common Equity soared by 181019.04% in 2021 and then crashed by 8512.77% in 2023.
  • Over the past 5 years, Vistagen Therapeutics' Common Equity (Quarter) stood at $80.0 million in 2021, then tumbled by 74.15% to $20.7 million in 2022, then soared by 496.31% to $123.3 million in 2023, then plummeted by 34.2% to $81.1 million in 2024, then tumbled by 37.23% to $50.9 million in 2025.
  • Its last three reported values are $50.9 million in Q4 2025, $66.3 million for Q3 2025, and $56.8 million during Q2 2025.